Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1618 1644 1647 1654 1693
This examiner grants 67% of resolved cases
Elly Gerald Stoica is an examiner in Tech Center 1600 and Art Unit 1618. She has 1242 resolved cases. The allowance rate is 66.9 percent. The median days to allowance is 933. This 933 days figure provides a timeline for applicants to consider during prosecution. The 1242 resolved cases offer a basis for these statistics. This data is specific to her work in Art Unit 1618.
The interview lift for this examiner is 22.5 percent. This lift indicates that the allowance rate changes when an interview is conducted. Practitioners can use this information to decide whether to request an interview. The 66.9 percent allowance rate is the baseline for applications assigned to her. Direct communication is a strategy that relates to the 22.5 percent lift. These figures from Tech Center 1600 help in planning prosecution steps. The 933 days median is a factor in managing expectations for patent pendency.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18332457 | Fibroblast Activation ImmunoPET for Detection of Fibrosis Activity | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18043554 | IMMUNOGLOBULIN E ANTIBODY COMPOSITIONS AND METHODS OF USE | Final Rejection | The Regents of the University of California |
| 18027993 | DISCOVERY AND USE OF IMMUNOGENIC PEPTIDES FOR THE TREATMENT AND PREVENTION OF CANCERS | Non-Final OA | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18540652 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE | Non-Final OA | Gilead Sciences, Inc. |
| 18514761 | ENGINEERED NEMO AND USES THEREOF | Non-Final OA | TRUSTEES OF DARTMOUTH COLLEGE |
| 18260741 | OVARIAN CANCER VACCINE | Final Rejection | Trustees of Dartmouth College |
| 18567159 | PHOTOACTIVATABLE GASDERMIN PROTEINS | Non-Final OA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 18380877 | COMPOSITIONS AND METHODS FOR TREATMENT OF PEDIATRIC PAIN | Non-Final OA | Children's Hospital Medical Center |
| 18272114 | TRANSDERMAL VACCINE | Non-Final OA | Oxford University Innovation Limited |
| 17085040 | Pharmaceutical Composition for Cancer Treatment | Final Rejection | Osaka University |
| 18513095 | TARGETED INHIBITION OF DKK3 TO SENSITIZE TUMORS TO IMMUNOTHERAPY | Non-Final OA | Duke University |
| 18318218 | CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18436808 | TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO MATRIPTASE ANTIBODIES | Non-Final OA | Georgetown University |
| 17997142 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TDP-43 PROTEINOPATHIES | Non-Final OA | SOLA BIOSCIENCES LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy